Welcome to our dedicated page for Cogent Biosciences news (Ticker: COGT), a resource for investors and traders seeking the latest updates and insights on Cogent Biosciences stock.
Cogent Biosciences, Inc. (NASDAQ: COGT) is a pioneering biotechnology company focused on developing precision therapies for genetically defined diseases. Headquartered in Waltham, MA, and Boulder, CO, Cogent's mission is to design rational, targeted therapies that treat the underlying causes of disease, thereby improving the lives of patients. The company's lead program, bezuclastinib, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation and other mutations in KIT exon 17. This mutation is a key driver of Systemic Mastocytosis (SM) and Advanced Gastrointestinal Stromal Tumors (GIST), both serious diseases dependent on oncogenic KIT signaling.
Bezuclastinib is undergoing rigorous clinical trials, with the PEAK, SUMMIT, and APEX trials all targeted toward specific genetic mutations associated with these diseases. The company has made significant strides in 2024, including the initiation of a new Phase 2 clinical trial of bezuclastinib in later line GIST patients in collaboration with the Sarcoma Alliance for Research through Collaboration (SARC), The Life Raft Group, and Dana-Farber Cancer Institute.
In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies focused on mutations in FGFR2, ErbB2, and PI3Kα. These programs aim to create therapies with potential best-in-class properties, targeting rare and genetically driven diseases.
The company recently secured $225 million in a private investment led by prominent investors, ensuring a robust financial position that supports its ambitious research and development goals. Cogent's financial stability is further reinforced by a strong cash runway projected to extend into 2027, allowing the company to complete its ongoing and planned clinical trials.
Latest News:
- February 26, 2024: Cogent announces a successful $225 million funding round, enhancing its financial stability.
- February 22, 2024: Positive Part 1b data from the ongoing SUMMIT trial evaluating bezuclastinib in NonAdvSM patients.
- February 14, 2024: New Phase 2 clinical trial of bezuclastinib in later line GIST patients announced in collaboration with SARC.
- January 9, 2024: Key milestones for 2024 highlighted at J.P. Morgan’s 42nd Annual Healthcare Conference.
For more detailed and updated information, visit Cogent Biosciences' official website and follow them on social media platforms like X (formerly known as Twitter) and LinkedIn.
Cogent Biosciences (Nasdaq: COGT) released updates for 2021 and guidance for 2022, highlighting progress in developing therapies for genetically defined diseases. In 2021, they initiated three late-stage clinical trials for bezuclastinib, targeting systemic mastocytosis and gastrointestinal stromal tumors. Preliminary data from the APEX trial is anticipated in early 2022. The formation of the Cogent Research Team aims to expand their pipeline of novel compounds. The company is set to host an R&D investor event in April 2022 to further discuss their research advancements.
Cogent Biosciences (Nasdaq: COGT) announced that CEO Andrew Robbins will participate in a fireside chat and one-on-one investor meetings at the Piper Sandler 33rd Annual Healthcare Conference from November 29 to December 2, 2021. The pre-recorded chat will be available starting at 10:00 a.m. ET and accessible until the conference concludes. Cogent focuses on precision therapies for genetically defined diseases, with its lead program, bezuclastinib, targeting the KIT D816V mutation linked to systemic mastocytosis and advanced gastrointestinal stromal tumors.
Cogent Biosciences, a biotechnology firm, announced its Q3 2021 financial results on November 10, 2021. The company reported R&D expenses of $14.8 million, significantly up from $5.0 million in Q3 2020. Net loss for the quarter was $19.1 million, an improvement compared to $50.0 million a year prior. Cash and cash equivalents as of September 30, 2021, stood at $202.9 million, sufficient to fund operations into 2024. The SUMMIT trial for bezuclastinib in systemic mastocytosis has begun, with other trials anticipated in 2022.
Cogent Biosciences, Inc. (Nasdaq: COGT) announced participation in the Jefferies London Healthcare Conference on November 18-19, 2021. CEO Andrew Robbins will engage in a fireside chat and one-on-one investor meetings. The chat starts at 4:00 AM ET on November 18 and can be accessed until 2:00 PM ET on November 19. Attendees can find the recording under the 'Events' tab on the investor relations page. Cogent focuses on developing precision therapies for genetically defined diseases, with bezuclastinib targeting the KIT D816V mutation linked to serious conditions.
Cogent Biosciences (Nasdaq: COGT) announced promising preclinical data for bezuclastinib, a selective KIT inhibitor, at the AACR-NCI-EORTC Virtual Conference. The study highlighted bezuclastinib's effectiveness against specific KIT mutations while showing minimal brain penetration, reducing potential CNS-related side effects. The company aims to initiate three clinical trials for Advanced Systemic Mastocytosis (AdvSM), Non-Advanced Systemic Mastocytosis (NonAdvSM), and Gastrointestinal Stromal Tumors (GIST) by the end of 2021, indicating a focused approach to developing targeted treatments for genetically defined diseases.
Cogent Biosciences (Nasdaq: COGT) will present preclinical data on bezuclastinib at the AACR-NCI-EORTC Virtual International Conference from October 7-10, 2021. The poster titled 'Preclinical data identifies bezuclastinib as a differentiated KIT inhibitor with unique selectivity to KIT D816V' will be available on their website shortly after 9:00 am ET on October 7.
Bezuclastinib targets the KIT D816V mutation related to systemic mastocytosis and various gastrointestinal stromal tumors. This research aims to enhance treatment options for patients with genetically driven diseases.
Cogent Biosciences (Nasdaq: COGT) announced its financial results for Q2 2021, reporting a net loss of $16.5 million, compared to $7.4 million in Q2 2020. R&D expenses surged to $12.4 million from $5.1 million year-over-year. The company initiated the Phase 2 APEX clinical study for bezuclastinib, targeting advanced systemic mastocytosis, and plans to start the SUMMIT study for non-advanced cases later in 2021. As of June 30, Cogent held $218.1 million in cash, sufficient to fund operations into 2024.
Cogent Biosciences (Nasdaq: COGT), a biotechnology firm focused on precision therapies for genetically defined diseases, will present at the Wedbush PacGrow Healthcare Conference on August 10, 2021, from 10:55 to 11:25 AM ET. CEO Andrew Robbins will lead the presentation. Attendees can access the live webcast and archived recording via the Cogent Biosciences investor relations website.
Cogent's lead therapy, bezuclastinib, targets KIT mutations linked to systemic mastocytosis and gastrointestinal stromal tumors.
Cogent Biosciences, Inc. (Nasdaq: COGT) announced that CEO Andrew Robbins will present at the Ladenburg Thalmann Virtual Healthcare Conference on July 14, 2021, from 2:00-2:25 pm ET. The event will highlight the company's focus on developing precision therapies for genetically defined diseases, including the clinical program for bezuclastinib, targeting the KIT D816V mutation linked to systemic mastocytosis and gastrointestinal stromal tumors. Interested parties can access the live webcast and archived recording through the Cogent Biosciences investor relations website.
Cogent Biosciences, Inc. (Nasdaq: COGT) announced that its CEO, Andrew Robbins, will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, from 11:30-11:55am ET. The company focuses on precision therapies for genetically defined diseases, with its lead program, CGT9486, targeting the KIT D816V mutation linked to systemic mastocytosis and gastrointestinal stromal tumors. Webcast access will be available on the Cogent investor relations website.
FAQ
What is the current stock price of Cogent Biosciences (COGT)?
What is the market cap of Cogent Biosciences (COGT)?
What does Cogent Biosciences, Inc. specialize in?
What is the main clinical program of Cogent Biosciences?
Where is Cogent Biosciences headquartered?
What recent achievements has Cogent Biosciences accomplished?
What are the financial prospects of Cogent Biosciences?
What other programs is Cogent developing besides bezuclastinib?
How can I stay updated with Cogent Biosciences' latest news?
What are Cogent Biosciences' key clinical trials?
Who are Cogent Biosciences' key collaborators?
How does bezuclastinib work?
